DEFA14A: Enfusion and Clearwater Analytics Announce Expiration of Hart-Scott-Rodino Act Waiting Period for Proposed Acquisition

Enfusion and Clearwater Analytics announced the expiration of the Hart-Scott-Rodino Act waiting period, moving their proposed acquisition closer to completion, expected in the second quarter of 2025.

Summary

• Enfusion, Inc. and Clearwater Analytics Holdings, Inc. announced the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period on February 24, 2025, at 11:59 p.m. Eastern Time.
• This expiration satisfies one of the closing conditions for Clearwater Analytics' proposed acquisition of Enfusion.
• The transaction is still subject to other customary closing conditions, including Enfusion shareholder approval.
• The companies anticipate completing the transaction in the second calendar quarter of 2025.
• Clearwater Analytics has filed a registration statement on Form S-4 with the SEC, which includes a proxy statement/prospectus for Enfusion stockholders.
• Investors and security holders are urged to read the registration statement, proxy statement/prospectus, and other relevant documents filed with the SEC carefully.
• These documents contain important information about the transaction, related risks, and other related matters.
• The companies have made available free copies of these documents on their websites and the SEC's website.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a key regulatory hurdle has been cleared for the acquisition, but the deal is still subject to shareholder approval and other conditions.

Positives

• The expiration of the HSR waiting period removes a significant hurdle to the completion of the acquisition.
• The companies still expect to complete the transaction by the second calendar quarter of 2025.
• Both Clearwater and Enfusion are providing easy access to relevant documents for investors to make informed decisions.

Risks

• The completion of the transaction is still subject to shareholder approval and other customary closing conditions.
• Delays in consummating the proposed transaction could occur.
• Required governmental and regulatory approvals of the proposed transaction could delay the consummation of the proposed transaction or cause the parties to abandon the proposed transaction.
• Enfusions stockholders may not approve the proposed transaction.
• Clearwater may not be able to successfully integrate the operations and technology of Enfusion.
• Clearwater may not be able to retain and incentivize the employees of Enfusion following the close of the acquisition.
• Clearwater may not be able to retain Enfusions clients.
• Cost savings, synergies and growth from the acquisition may not be fully realized or may take longer to realize than expected.

Future Outlook

The companies expect to complete the transaction in the second calendar quarter of 2025, subject to the satisfaction or waiver of customary closing conditions, including the receipt of Enfusion shareholder approval.

Industry Context

The acquisition of Enfusion by Clearwater Analytics reflects a trend of consolidation in the investment management software and services industry, as companies seek to offer more comprehensive solutions and expand their market reach.

Comparison to Industry Standards

• Clearwater Analytics competes with companies like BlackRock, SS&C Technologies, and SimCorp in providing investment management solutions.
• Enfusion competes with companies like Bloomberg, FactSet, and Charles River Development in providing front-to-back office solutions for investment managers.
• The acquisition aims to create a more integrated platform, potentially offering a competitive advantage over firms with less comprehensive offerings.

Stakeholder Impact

• Shareholders of Enfusion will vote on the proposed transaction.
• Employees of Enfusion may experience changes as a result of the acquisition.
• Customers of both Clearwater and Enfusion may benefit from a more integrated platform.

Next Steps

• Enfusion will seek shareholder approval for the merger agreement.
• Both companies will work to satisfy the remaining closing conditions.
• Clearwater will continue to work towards integrating Enfusion's operations and technology.

Key Dates

Keywords

acquisition, Enfusion, Clearwater Analytics, merger, HSR Act, investment management, SaaS, Hart-Scott-Rodino, antitrust